Lite Strategy, Inc.

Listed Company

LITSCIK 0001262104NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

Net Income

$-16.00M

Total Assets

$18.29M

Equity

$16.93M

Shares Out

36.36M

Op. Cash Flow

$-20.84M

Business

Lite Strategy, Inc. is a pharmaceutical company focused on developing and commercializing novel oncology therapies and deploying a digital asset-based treasury strategy. The company’s main offerings include drug candidates voruciclib (an oral CDK9 inhibitor) and zandelisib (an oral PI3Kδ inhibitor), alongside R&D, licensing, strategic partnerships and potential Litecoin treasury/mining activities. Key business activities are clinical and preclinical development, out-licensing and collaborations, and digital-asset management through agreements with asset managers and advisors. Products and services are developed and distributed via clinical trial networks, partner collaborations and global regulatory channels.

Summary from filing dated 2025-09-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Revenues	0	65	49	41	35
Research and development	4	17	52	86	69
General and administrative	14	23	33	31	24
Impairment of long-lived assets	0	11	0	—	—
Total operating expenses	17	51	86	116	95
(Loss) income from operations	−17	15	−37	−75	−60
Interest and dividend income	1	3	3	284,000	510,000
Gain on disposition of a non-financial asset	500,000	0	—	—	—
Other expense, net	−16,000	−41,000	−22,000	−6,000	486,000
Total other income, net	2	3	5	21	19
Net (loss) income	−16	18	−32	−54	−41
Basic (per share)	−2.39	2.67	−4.78	−8.75	−0.37
Diluted (per share)	−2.39	2.67	−4.78	−9.99	−0.6
Basic (shares)	7	7	7	6	113
Diluted (shares)	7	7	7	6	114

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	18	4	17	16	9
Short-term investments	0	35	84	138	145
Prepaid expenses and other current assets	274,000	2	7	4	4
Total current assets	18	41	108	167	165
Operating lease right-of-use asset	0	200,000	12	9	8
Property and equipment, net	0	392,000	1	2	2
Total assets	18	41	121	178	174
Accounts payable	176,000	3	6	8	6
Accrued liabilities	1	5	12	11	8
Total current liabilities	1	8	20	24	20
Total liabilities	1	8	96	125	125
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding	0	0	0	0	0
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at June 30, 2025 and June 30, 2024	0	0	0	0	0
Additional paid-in capital	421	421	431	427	369
Accumulated deficit	−404	−388	−406	−374	−320
Total stockholders' equity	17	33	25	52	49
Total liabilities and stockholders' equity	18	41	121	178	174

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net (loss) income	−16	18	−32	−54	−41
Share-based compensation	−144,000	2	4	8	10
Impairment of long-lived assets	0	11	0	—	—
Noncash lease expense	214,000	2	1	909,000	0
Depreciation expense	368,000	383,000	386,000	326,000	285,000
Loss on disposal of property and equipment	14,000	32,000	0	—	—
Unbilled receivables	0	85,000	10	−2	−5
Prepaid expenses and other current assets	2	5	−3	−21,000	−1
Accounts payable	−3	−3	−2	2	4
Accrued liabilities	−4	−7	2	2	2
Deferred revenue	0	−65	−31	16	−4
Operating lease liability	0	−14	−1	—	—
Net cash used in operating activities	−21	−50	−52	−49	−32
Purchases of short-term investments	0	−58	−102	−273	−420
Proceeds from maturity of short-term investments	35	107	155	280	446
Proceeds from sale of property and equipment	10,000	0	—	—	—
Proceeds from the disposition of a non-financial asset	500,000	0	—	—	—
Purchases of property and equipment	0	−7,000	−35,000	−479,000	−708,000
Net cash provided by investing activities	35	49	54	7	25
Payment of cash dividend	0	−12	0	—	—
Payment of financing costs	0	−208,000	0	—	—
Net cash used in financing activities	0	−12	−40,000	49	3
Net increase (decrease) in cash and cash equivalents	14	−13	1	7	−4
Re-measurement of right-of-use asset and related lease liability upon lease modification	0	−22,000	0	—	—
Re-measurement of right-of-use asset for direct costs associated with lease modification	0	181,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro